


Granzyme B cleaves Tenascin-C to release its C-terminal domain in rheumatoid arthritis

Alexandre Aubert, Amy Liu, Martin Kao, Jenna Goeres, Katlyn C. Richardson, Lorenz Nierves, Karen Jung, Layla Nabai, Hongyan Zhao, Gertraud Orend, Roman Krawetz, Philipp F. Lange, Alastair Younger, Jonathan Chan, David J. Granville



Supplementary figure 1: Western-blot analysis demonstrating that after N-deglycosylation by PNGase F, rhTNC is more sensitive to proteolytic degradation by rhGzmB.


A.

	Mouse	Rat	Human	Monkey	Pig	Bovine
GzmB-Mouse	/	80.57	67.76	66.94	66.94	67.62
GzmB-Rat	80.57	/	68.98	69.80	67.76	67.62
GzmB-Human	67.76	68.98	/	87.85	72.24	72.36
GzmB-Monkey	66.94	69.80	87.85	/	72.24	71.14
GzmB-Pig	66.94	67.76	72.24	72.24	/	76.73
GzmB-Bovine	67.62	67.62	72.36	71.14	76.73	/


B.

GzmB-Mouse	--MKILLLLTSLASRTKAGEIIIGGHEVVKPHSRPYMALLSIKDQQ-PEAICGGFLIRED	57
GzmB-Rat	--MKLLLLLFSFLAPKTEAGEIIIGGHEAKPHSRPYMAYLQIMDEYSGSKKCGGFLIRED	58
GzmB-Human	MQPILL--LLAFLLPRADAGEIIIGGHEAKPHSRPYMAYLMIWDQK-SLKRCGGFLIRDD	57
GzmB-Monkey	MQPILL--LLAFLLPRTDAGEIIIGGHEAKPHSRPYMAYLMIWDQM-SLKRCGGFLIRED	57
GzmB-Pig	MQPLLLLSLAFLLPPRAEAGEIIIGGHEAKPHSRPYMAYLQIQDQD-NRSRCGGFLIRED	59
GzmB-Bovine	MKPLLL--LVAFLLTPRAKAGEIIIGGHEAKPHSRPYMAYLQYWNQD-VQSRCGGFLVRQD	57
	:* ::* * :.*****.***** * :: *****:*	
	<i>His⁵⁹</i> FVLTAAHCEGSIINVTLGAHNIKEQEK TQQVIPMVKCIPHDPYNP KTFNSDIMLLKLSK <i>Asp¹⁰³</i>	117
GzmB-Rat	FVLTAAHCSGSKINVTLGAHNIKEQEQIIPVVKIIPHPAYNSKTISNDIMLLKLSK	118
GzmB-Monkey	FVLTAAHCWGSSINVTLGAHNIKEQEPQQFIPVKRPIHPAYNPKNFSNDIMLLQLERK	117
GzmB-Monkey	FVLTAAHCWGSSINVTLGAHNIKEQERTQQIIPVKRAIPHPAYNPNFNSNDIMLLQLERK	117
GzmB-Pig	FVLTAHCWGSSINVTLGAHNIKNRE-DQQVIPVRKAICHDPYNEKRISNDIMLLQLERK	118
GzmB-Bovine	FVLTAHCNGSIIKVTLGAHNIKQERTQQVIRVRAISHPDYNPKNFSNDIMLLKLERK	117
	***** ** * :*****: * ** * : * * * : :*****:*	
GzmB-Mouse	AKRTRAVRPLNPRNVNPKPGDVCYVAGWGRMAPMGKYSNTLQEVELTVQKDRCECSYF	177
GzmB-Rat	AKRSSAVKPLNPRNVNPKPGDVCYVAGWGLGPMGKYSNTLQEVELTVQEDQKCESYL	178
GzmB-Human	AKRTRAVQPLRPLSNKAQVKPGQTCVAVGWGQTAPLKGHSHTLQEVKMTVQEDRKCESDL	177
GzmB-Monkey	AKRTRAVQPLRPLSNKAQVKPGQACDVAVGWGQTPDGKYSHTLQEVKLTVEEDQTKSRL	177
GzmB-Pig	AKLTAVKVTLSLPGAKARVVKPGQVCSVAVGWGQVE-RGIYDTLQEVKLTQKQDCDSYL	177
GzmB-Bovine	AKQTSAVKPLSLPRAKARVVKPGQTCVAVGWGRDS-TDTYADTLQEVKLTQKQKCEAYL	176
	** : ** : * ** :.*****.*****: . :.*****: :.:* :. : :	
	<i>Ser¹⁹⁸</i>	
GzmB-Mouse	KNRYNKTNQICAGDPKTKRASFRGDSGGPLVCKKVAAGIVSYGKDGSPRAFTKVSFSL	237
GzmB-Rat	KNYFDKANEICAGDPKTKRASFRGDSGGPLVCKKVAAGIVSYGQNDGSTPRAFTKVSFSL	238
GzmB-Human	RHYDSTIELCVGDPEIKKTSFKGDSGGPLVCKKVAAGIVSYGRNNGMPRACTKVSFV	237
GzmB-Monkey	GHYDSTVELCVGDPEIQKASFKGDSGGPLVCKKVAAGIVSYGRNGKPPRVCTKVSFV	237
GzmB-Pig	PNYYNGTQLCVGDPKKQATFKGDSGGPLVCNNVAAGIVSYGKKGTPRACTKVSFSL	237
GzmB-Bovine	RNFYNRAIQLCVGDPKTKASFKGDSGGPLVCDNVAAGIVSYGKRKGSTPRAFTKVSFSL	236
	: : :.*****: :.:*****:.* ***** .:* * . *****:*	
GzmB-Mouse	SWIKKTMKSS	247
GzmB-Rat	SWIKKTMKKS	248
GzmB-Human	HWIKKTMKRY	247
GzmB-Monkey	RWIKKTMKRH	247
GzmB-Pig	PWIKKIMKSL	247
GzmB-Bovine	PWIKKTMKSL	246
	**** **	




C.



Supplementary figure 2: (A) Identify matrix between amino-acid sequences of GzmB from different species, represented as percentage of identity (same amino-acid at the same position). Identity percentage between human and mouse GzmB is indicated in bold/red. (B) Amino-acid sequence alignment between GzmB from different species. Residues labelled with (*) are identical, residues labelled with (:) are highly conserved and residues labelled with (.) are poorly conserved. Amino-acids from the catalytic triad (His⁵⁹-Asp¹⁰³-Ser¹⁹⁸) are identified in bold and are highlighted in yellow. (C) 500 ng of lab-generated mTNC was incubated with (or without) 50 nM rmGzmB for 24h, 48, or 72h at 37°C and analyzed by western blot probing for mTNC. Arrowheads are pointing at the 30 kDa fragments of mTNC generated by mGzmB digestion.




Supplementary figure 3: Immunofluorescence staining performed against immobilized rhTNC non-digested or digested with 50 nM GzmB for 24h. Bars, 200 μm .




Supplementary figure 4: (A) Schematic representation of the experimental procedure used to investigate the direct impact of GzmB on fibroblast behaviours. (B) Phase-contrast microscopy performed on primary human dermal fibroblasts cultured for 72 h onto non-coated (NC) and non-digested (ND) wells, NC wells digested with rhGzmB, or TNC coated wells digested with rhGzmB as indicated in (A). Bars, 400 μm . (C) Percentage of cell viability obtained by MTS assay performed on primary human dermal fibroblasts cultured

for 72 h onto NC/ND wells, NC wells digested with rhGzmB, wells coated with ND rhTNC, or wells coated with rhTNC and digested with rhGzmB. Results were normalized compared to their respective control condition and are represented as means \pm SD from 2 independent experiments. NC = non-coated. ND = non-digested.




Supplementary figure 5: (A) Phase-contrast microscopy performed on keratinocytes (HaCaTs, left panel) or lung epithelial cells (Beas2B, right panel) cultured for 72 h onto non-coated (NC) wells, wells coated with non-digested (ND) rhTNC, or wells coated with rhTNC and digested for 24h with 50 nM rhGzmB. Bars, 400 μ m. (B and C) Percentage of cell viability obtained by MTS assay performed on HaCaTs (B) or Beas2B (C) cultured for 72 h onto non-coated (NC) wells, wells coated with non-digested (ND) rhTNC, or wells

coated with rhTNC and digested for 24h with 50 nM rhGzmB. Results were normalized compared to the NC condition and are represented as means \pm SD from 3 independent experiments. NC = non-coated. ND = non-digested.



Supplementary figure 6: Violin plots showing the distribution of peptide lengths observed after rhTNC digestion by rhGzmB for 24h (red) or 48h (blue). The overlaying box plots were in the style of Tukey: the box boundaries represent Q1 and Q3 while the line within the box represents the median; whiskers extend from the upper and lower quartiles to the maximum and minimum values, respectively, with the outliers excluded. Outliers were defined as $1.5 \times \text{IQR}$ of Q1 or Q3 and are displayed as points beyond the minimum and maximum values, respectively.



Supplementary figure 7: (A and B) Correlation (Spearman rank-order) between TNC and GzmK levels (**A**) or between GzmK and GzmB levels (**B**) in HC, OA, RA and IA patient's synovial fluids measured by ELISA. ns = not significant, $*=p<0.05$.